- Home
- NMCO vs TBPH Comparison
NMCO vs TBPH Comparison
Compare NMCO & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- TBPH
- Stock Information
- Founded
- NMCO 2019
- TBPH 2013
- Country
- NMCO United States
- TBPH United States
- Employees
- NMCO N/A
- TBPH N/A
- Industry
- NMCO Finance/Investors Services
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- NMCO Finance
- TBPH Health Care
- Exchange
- NMCO Nasdaq
- TBPH Nasdaq
- Market Cap
- NMCO 577.1M
- TBPH 464.5M
- IPO Year
- NMCO N/A
- TBPH N/A
- Fundamental
- Price
- NMCO $10.36
- TBPH $10.63
- Analyst Decision
- NMCO
- TBPH Buy
- Analyst Count
- NMCO 0
- TBPH 4
- Target Price
- NMCO N/A
- TBPH $14.50
- AVG Volume (30 Days)
- NMCO 207.6K
- TBPH 319.2K
- Earning Date
- NMCO 01-01-0001
- TBPH 08-04-2025
- Dividend Yield
- NMCO 5.43%
- TBPH N/A
- EPS Growth
- NMCO N/A
- TBPH N/A
- EPS
- NMCO N/A
- TBPH N/A
- Revenue
- NMCO N/A
- TBPH $65,266,000.00
- Revenue This Year
- NMCO N/A
- TBPH $43.53
- Revenue Next Year
- NMCO N/A
- TBPH N/A
- P/E Ratio
- NMCO N/A
- TBPH N/A
- Revenue Growth
- NMCO N/A
- TBPH 6.11
- 52 Week Low
- NMCO $8.52
- TBPH $7.44
- 52 Week High
- NMCO $11.64
- TBPH $11.82
- Technical
- Relative Strength Index (RSI)
- NMCO 42.94
- TBPH 57.46
- Support Level
- NMCO $10.35
- TBPH $10.42
- Resistance Level
- NMCO $10.70
- TBPH $11.00
- Average True Range (ATR)
- NMCO 0.11
- TBPH 0.42
- MACD
- NMCO -0.03
- TBPH -0.03
- Stochastic Oscillator
- NMCO 2.86
- TBPH 35.50
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).